I agree that this site is using cookies. You can find further informations here.
X
Peyrin-Biroulet, L.
1916  results:
Search for persons X
?
1

P931 Burden of disease among Ulcerative Colitis patients wi..:

Armuzzi, A ; Danese, S ; Barreiro-de Acosta, M...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1694-i1696 , 2024
Link: https://doi.org/10.1093/..
 
?
2

P752 Difficult-to-treat inflammatory bowel disease: effecti..:

Caron, B ; Habert, A ; Bonsack, O...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1405-i1405 , 2024
Link: https://doi.org/10.1093/..
 
?
3

P1013 Placebo rates in Crohn's disease: An individual patie..:

Solitano, V ; Hogan, M ; Singh, S...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1830-i1832 , 2024
Link: https://doi.org/10.1093/..
 
?
4

P927 Long-term outcomes of risankizumab in Crohn's disease:..:

Fumery, M ; Caron, B ; Hébuterne, X...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1686-i1686 , 2024
Link: https://doi.org/10.1093/..
 
?
5

DOP18 Efficacy of risankizumab versus ustekinumab by baseli..:

Peyrin-Biroulet, L ; Colombel, J F ; D'Haens, G...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i104-i105 , 2024
Link: https://doi.org/10.1093/..
 
?
6

OP03 Efficacy and safety of the oral selective sphingosine-..:

Sands, B E ; Panaccione, R ; D'Haens, G...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i4-i5 , 2024
Link: https://doi.org/10.1093/..
 
?
7

P1071 Patient preferences for adalimumab in inflammatory bo..:

Caron, B ; Seksik, P ; Buisson, A...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1925-i1925 , 2024
Link: https://doi.org/10.1093/..
 
?
8

Risk of anti-TNF therapy on pregnancy, breastfeeding, live ..:

Bendaoud, S. ; Nahon, S. ; Beaugerie, L....
Digestive and Liver Disease.  , 2024
Link: https://doi.org/10.1016/..
 
?
9

P225 Mucosal transcriptomic profiles associated with clinic..:

Magro, F ; Feagan, B G ; Rogler, G...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i561-i562 , 2024
Link: https://doi.org/10.1093/..
 
?
10

P954 Cumulative response to guselkumab through week 24 of i..:

Rubin, D ; Sands, B ; Lichtenstein, G...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1732-i1733 , 2024
Link: https://doi.org/10.1093/..
 
?
11

P051 Diets enriched in fat and sugar and sex-dependant resp..:

Touly, N ; Arnone, D ; Caron, B...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i316-i317 , 2024
Link: https://doi.org/10.1093/..
 
?
12

DOP11 Disease clearance after 16 weeks of treatment with ve..:

Jairath, V ; Zou, G ; Adsul, S...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i92-i93 , 2024
Link: https://doi.org/10.1093/..
 
?
13

DOP12 Efficacy and safety of obefazimod in UC patients at w..:

Vermeire, S ; Peyrin-Biroulet, L ; Danese, S...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i94-i95 , 2024
Link: https://doi.org/10.1093/..
 
?
14

P430 The influence of persistent organ damage on IFX pharma..:

Magro, F ; Fernandes, S ; Patita, M...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i883-i884 , 2024
Link: https://doi.org/10.1093/..
 
?
15

OP12 Mirikizumab improves fatigue, bowel urgency, and quali..:

Travis, S ; Hisamatsu, T ; Fischer, M...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i21-i23 , 2024
Link: https://doi.org/10.1093/..
 
1-15